Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

Detailed summary
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and…
ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that its two core assets are covered by China's 2026 National Reimbursement Drug List (NRDL), providing more patients with greater access to innovative treatment options. Specifically:
With these developments, all approved indications for both of Ascentage Pharma's novel drugs are now covered by the NRDL. The updated NRDL will officially take effect on January 1, 2027.
Lisaftoclax is a novel, oral, Bcl-2 selective inhibitor independently developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and hence restoring the normal apoptosis process in cancer cells. Approved in China in July 2025, lisaftoclax became the first domestically developed, original Bcl-2 inhibitor to receive marketing approval in the country. Its inclusion in the updated NRDL is expected to significantly improve treatment accessibility for patients with CLL/SLL in China, enabling more patients to gain timely access to new treatment options.
Olverembatinib is a novel, oral, third-generation BCR-ABL inhibitor independently developed by Ascentage Pharma, with support from China's National Major New Drug Innovation Program. It is jointly commercialized in China by Ascentage Pharma and Innovent Biologics. Approved in China in November 2021, olverembatinib became the first third-generation BCR-ABL inhibitor to receive marketing approval in the country. The successful renewal of its NRDL coverage will continue to benefit more patients with CML in China by further improving the affordability and accessibility of long-term treatment.
Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, commented…
Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)




